Retatrutide 2026: 28.3% Weight Loss Confirmed — Complete Guide

What's New: July 2026 Update

• TRIUMPH-4 confirmed final: 28.7% weight loss at 68 weeks — peer-reviewed data, December 2025
• TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients; 30.3% at 104 weeks in a BMI ≥35 extension cohort
• TRANSCEND-T2D-1 confirmed (topline March 2026, published June 2026): First completed diabetes-specific Phase 3 trial — -2.0% HbA1c and 16.8% weight loss in 537 patients, a separate program from TRIUMPH
• NDA timeline unchanged: industry estimates continue to expect Q4 2026 filing, based on standard practice following TRIUMPH-1's primary readout
• Timeline unchanged: FDA approval late 2027, market launch Q1–Q2 2028
• OSA data confirmed (ADA June 6, 2026): TRIUMPH-1's nested sleep apnea substudy showed 60.6% AHI reduction from a severe-OSA baseline of 58.6 events/hour
• This page updates after every trial announcement — bookmark for the latest

Introduction

Retatrutide stands at the forefront of obesity medicine — a first-in-class triple hormone agonist that has demonstrated some of the highest weight loss efficacy ever recorded in clinical trials. With TRIUMPH-4 (December 2025, 28.7% weight loss), TRIUMPH-1 (May 2026, 28.3% in 2,339 patients), and now TRANSCEND-T2D-1 (June 2026, the first diabetes-specific Phase 3 readout) all confirmed, this investigational medication is rapidly approaching regulatory review.

This guide synthesizes everything currently known about retatrutide: the TRIUMPH Phase 3 program, the separate TRANSCEND-T2D diabetes program, the regulatory pathway, competitive positioning, safety data, and realistic projections for when patients might access this medication.

Retatrutide 2026: Status at a Glance

What is Retatrutide? Understanding the Triple Agonist Mechanism

Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly, simultaneously activating GLP-1, GIP, and glucagon receptors.

GLP-1 activation slows gastric emptying and suppresses appetite — the mechanism shared by semaglutide (Wegovy). GIP activation enhances insulin secretion and works synergistically with GLP-1, the mechanism that let tirzepatide (Zepbound) outperform semaglutide. Glucagon activation is retatrutide's unique third mechanism, increasing energy expenditure and fat oxidation — contributing to its larger weight loss effect versus dual agonists.

The Evolution of Metabolic Hormone Agonists

The TRIUMPH Phase 3 Program: A Comprehensive Overview

TRIUMPH is Eli Lilly's global registrational Phase 3 program for retatrutide, begun in 2023, having enrolled more than 5,800 participants. Per the program's published design paper (Giblin et al., Diabetes, Obesity and Metabolism, 2026), the core registrational program consists of four trials:

TRIUMPH-1 (NCT05929066): 80-week weight management basket trial, adults with obesity/overweight without diabetes (N=2,339), with knee osteoarthritis and obstructive sleep apnea substudies nested inside it. Complete — 28.3% weight loss (12mg).

TRIUMPH-2 (NCT05929079): 80-week weight management basket trial, adults with obesity/overweight and type 2 diabetes — also with nested OSA/OA substudies. Ongoing, results expected later 2026.

TRIUMPH-3 (NCT05882045): 80-week weight management trial in adults with obesity/overweight and established cardiovascular disease. Ongoing, results expected later 2026.

TRIUMPH-4 (NCT05931367): 68-week standalone knee osteoarthritis trial, adults with obesity/overweight without diabetes (N=445, randomized 1:1:1 to 9mg, 12mg, or placebo). Complete — 28.7% weight loss (12mg).

Beyond these four, Lilly has registered additional TRIUMPH-numbered studies — including trials in weight maintenance (TRIUMPH-6, NCT06859268) and chronic low back pain (TRIUMPH-7, NCT07035093) — bringing the total program to eight trials, plus a separate, longer-horizon cardiovascular and kidney outcomes trial, TRIUMPH-Outcomes (NCT06383390), enrolling roughly 10,000 participants with established cardiovascular disease. TRIUMPH-Outcomes is not required for the initial obesity indication and isn't expected to report until 2028–2029.

TRIUMPH Trials: Individual Study Breakdown

TRIUMPH-1: General Obesity Population (COMPLETE)

Results confirmed May 21, 2026. 2,339 adults without diabetes, randomized to 4mg/9mg/12mg/placebo over 80 weeks.

Key results (12mg): 28.3% average weight loss (70.3 lbs); 45.3% achieved ≥30% weight loss; 65.3% reduced BMI below 30. A blinded extension in participants with baseline BMI ≥35 reached 30.3% weight loss (85.0 lbs) at 104 weeks — no plateau. Discontinuation due to adverse events: 4.1% (4mg) / 6.9% (9mg) / 11.3% (12mg) vs. 4.9% placebo — notably lower than TRIUMPH-4.

TRIUMPH-1 is the most important trial in the program for FDA purposes — it's the broad general obesity population retatrutide will be prescribed to after approval, and the dataset Lilly will anchor its NDA on. For a complete overview of all results, see our comprehensive clinical results guide.

TRIUMPH-4: Obesity with Knee Osteoarthritis (COMPLETE)

Results announced December 2025. 445 participants with obesity and knee osteoarthritis, without diabetes, randomized 1:1:1 to 9mg, 12mg, or placebo over 68 weeks.

Key results (12mg): 28.7% average weight loss; significant improvement in WOMAC pain scores, with more than 1 in 8 participants becoming completely free of knee pain. Side effects included dysesthesia in 8.8% (9mg) and 20.9% (12mg) of patients vs. 0.7% placebo — the most distinctive side effect of this drug class. For management strategies, see our complete side effects guide.

TRIUMPH-2: Obesity with Type 2 Diabetes

Ongoing, results expected later 2026. Like TRIUMPH-1, this is a basket trial with nested OSA/OA substudies — but enrolling participants who also have type 2 diabetes. Results here will determine whether retatrutide pursues a combined obesity-and-diabetes indication. (Note: this is distinct from the separate TRANSCEND-T2D program below, which targets diabetes specifically rather than obesity-with-diabetes.)

TRIUMPH-3: Obesity with Established Cardiovascular Disease

Ongoing, results expected later 2026. Evaluates retatrutide's efficacy and safety in patients with existing cardiovascular disease — distinct from the larger, longer-horizon TRIUMPH-Outcomes MACE trial described above.

The TRANSCEND-T2D Program: A Separate Diabetes-Specific Track

Distinct from TRIUMPH, Eli Lilly runs TRANSCEND-T2D — a dedicated, multi-trial Phase 3 program focused specifically on type 2 diabetes, having enrolled more than 2,050 participants since 2024.

TRANSCEND-T2D-1 (NCT06354660), the program's first trial, reported topline results March 19, 2026, with full publication in The Lancet in June. In 537 patients with type 2 diabetes (85% treatment-naive), the trial showed HbA1c reductions up to 2.0% and weight loss up to 16.8% at 40 weeks, with no plateau. Both dysesthesia and discontinuation rates were notably lower than in TRIUMPH-4's obesity population (discontinuation 2.2% / 4.5% / 5.1% by dose vs. 0.0% placebo).

For the full breakdown, see our TRANSCEND-T2D-1 results guide. Additional TRANSCEND-T2D readouts are expected through 2026–2027.

FDA Approval Timeline: From NDA to Market Launch

NDA Submission: Q4 2026

Eli Lilly will compile efficacy data primarily from TRIUMPH-1, supportive data from TRIUMPH-4, the safety database across all trials, and manufacturing/labeling documentation.

FDA Review Period: 10–12 Months

Standard review is 10 months; priority review is 6 months, possible given unmet need. Key FDA considerations will include the dysesthesia signal (up to 20.9% at the highest dose) and what comorbidity criteria will define the indication.

PDUFA Date and Launch

If the NDA is filed Q4 2026, expect FDA action around late 2027 (priority review) or Q1 2028 (standard review), with commercial launch following 1–3 months later for manufacturing and distribution setup.

International Approvals

The European Medicines Agency is expected to receive a parallel submission, with approval typically following the FDA by 3–6 months. Other major markets (Japan, Canada, Australia) typically follow 6–12 months post-FDA.

For a detailed breakdown, see our FDA approval timeline guide.

How Retatrutide Compares: Current Competitive Landscape

For an in-depth comparison, see our comprehensive three-way medication comparison. Pipeline competitors include CagriSema (Novo Nordisk) and Survodutide (Boehringer Ingelheim), both in Phase 3.

Safety Profile: What 2026 Data Tells Us

Discontinuation appears lowest in the diabetes-specific TRANSCEND-T2D-1 population — the reason isn't fully established but may relate to population or trial-duration differences. For comprehensive long-term safety data, see our long-term safety analysis and dysesthesia guide.

Who Will Be Eligible for Retatrutide? Predicted Criteria

Expected indication: BMI ≥30, or BMI ≥27 with a weight-related comorbidity — matching semaglutide and tirzepatide. Predicted contraindications: personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy, and history of severe pancreatitis.

For details, see our complete eligibility guide.

What Healthcare Providers Should Know

Set realistic expectations: 28.3–28.7% is an average, and a meaningful share of patients won't reach surgical-level outcomes. Monitor for dysesthesia (up to 20.9% at 12mg) — most cases are mild, but discuss tolerability proactively. Manage GI side effects through slow dose escalation. Screen for absolute contraindications (MTC/MEN 2 history). For diabetes patients specifically, TRANSCEND-T2D-1 suggests meaningfully better tolerability than the general obesity population — worth factoring into expectation-setting.

What Patients Should Do Now

2026: TRIUMPH-1 and TRANSCEND-T2D-1 are confirmed — approval remains on track. If you currently qualify for semaglutide or tirzepatide, don't wait for retatrutide. Review your insurance coverage now, since many plans restrict GLP-1-class medications.

Late 2027: Watch for the FDA decision and schedule a provider appointment to discuss eligibility ahead of launch.

2028: Expect possible supply constraints in the first months post-launch; enroll in patient assistance programs if cost is a barrier.

Conclusion: The Future of Obesity and Diabetes Treatment

Retatrutide's results across two separate programs — 28.3–28.7% weight loss in TRIUMPH-1/4, and -2.0% HbA1c with 16.8% weight loss in TRANSCEND-T2D-1 — represent a genuine advance for a single medication addressing both severe obesity and type 2 diabetes. TRIUMPH-2 and TRIUMPH-3, expected later in 2026, will complete the picture for diabetes-with-obesity and cardiovascular populations. By late 2027, we'll know whether the FDA agrees the efficacy justifies the tolerability trade-offs.

Retatrutide remains investigational. But the accumulating, independently-verified data across multiple trials and populations says it will soon become one of the highest-efficacy options in obesity and diabetes medicine.

Sources & References

• Eli Lilly press release: TRIUMPH-1 Phase 3 topline results. May 21, 2026.
• Eli Lilly press release: TRIUMPH-4 Phase 3 Trial Results. December 2025.
• Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026;28(1):83-93.
• Bajaj HS, et al. "Efficacy and safety of retatrutide... (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026.
• Eli Lilly. TRANSCEND-T2D-1 Phase 3 topline results announcement. March 19, 2026.
• Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023.
• ClinicalTrials.gov: NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), NCT05882045 (TRIUMPH-3), NCT05931367 (TRIUMPH-4), NCT06383390 (TRIUMPH-Outcomes), NCT06354660 (TRANSCEND-T2D-1).